Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Showing posts with label Pennsylvania. Show all posts
Showing posts with label Pennsylvania. Show all posts

Sunday, May 10, 2015

Pa. Law Prohibits Needle Exchanges That Can Save Lives

Tens of thousands of Pennsylvanians crave daily injections of heroin. Beyond the threat of overdose is the threat of being exposed to HIV and hepatitis C, both deadly and expensive illnesses that are easily spread through contaminated needles.

But in Pennsylvania, distributing sterile syringes is a criminal act.

For years, Dianna Pagan feared that giving out clean syringes in Reading would land her in jail. Officials there recently agreed to let her needle exchange operate, though she’s faced numerous setbacks for more than a decade, including being shut down following the threat of prosecution.

Friday, February 27, 2015

Baker's hepatitis C screening bill gains House approval

HARRISBURG - The Pennsylvania House of Representatives this week approved House Bill 59 authored by Rep. Matt Baker (R-Tioga/Bradford/Potter), chairman of the House Health Committee, that would require physicians to offer hepatitis C screening to patients born between 1945 and 1965.

"If it is determined a patient tests positive for hepatitis C, he or she would then be offered follow-up health care," said Baker. "Treatment today can vastly improve a person's quality of life and result in better health outcomes, including being cured of the disease."

Baker noted that actively screening for hepatitis C, as opposed to waiting for symptoms and more serious diseases to arise from having the disease, will also result in major cost savings for taxpayers. In fact, the estimated medical costs associated with treating Baby Boomers with hepatitis C, many of whom will age into the Medicare system at age 65, will rise from $30 billion in 2009 to $85 billion annually by 2024.

Tuesday, February 10, 2015

Pa. considering moving away from costly Hepatitis C treatment

(Harrisburg) -- Pennsylvania might move away from a stunningly expensive prescription drug treatment for Medicaid patients with Hepatitis C, but the Commonwealth won't save as much as other states.

Missouri is one of the first states to move away from Sovaldi, which costs $1,000 a pill.

Pennsylvania might do the same, but the state's Medicaid program is waiting on final offers from two competitors that provide other drugs recently approved by the FDA for Hepatitis C treatment.

Read more...

Monday, January 5, 2015

New drugs offer hope, barriers for hepatitis C patients

For patients with hepatitis C, the last year has brought great hope: New drugs that are highly effective with few side effects. But their high cost has led Medicaid officials in Pennsylvania and other states to put up barriers for patients, treating only the sickest ones and leaving many others to wait.

"This is an unprecedented approach we've had to take with these drugs," said Terri Cathers, pharmacy director for Pennsylvania's Office of Medical Assistance Programs. "We've not done this before for other treatments as long as I've been in the business."

The approach, she said, is a direct result of the cost, which can range up to $150,000 per patient.

Read more at http://www.philly.com/philly/health/20150104_New_drugs_offer_hope__barriers_for_hepatitis_C_patients.html#HAz2fKXJskLoLyFP.99